pharmaceutical research - Publications - Faculty & Research

Robert P. Luciano

Luciano generated top-level financial performance while streamlining Schering’s business operations. He divested Schering’s non-healthcare related business lines and was one of the first pharmaceutical executives to recognize the... View Details

Keywords: Healthcare

John J. Horan

Through heavy investments in research and development, Horan led Merck to become the leading U.S.-based manufacturer of prescription drugs in the world. Under Horan’s leadership, Merck doubled their spending on View Details

Keywords: Healthcare

Forthcoming
Article

Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation

By: Amitabh Chandra, Jennifer Kao, Kathleen L. Miller and Ariel Dora Stern

Regulators of new products confront a tradeoff between speeding a product to market and collecting additional product quality information. The FDA's Breakthrough Therapy Designation (BTD) provides an opportunity to understand if regulators can use new policy to... View Details

Keywords: Innovation and Invention; Governing Rules, Regulations, and Reforms; Government Administration; Research and Development; Pharmaceutical Industry

Citation

Find at Harvard

Register to Read

The first non-Lilly family member to serve as president, Beesley joined the pharmaceutical company at the age of 20, and worked in a variety of positions before becoming an executive level manger. Under Beesley’s leadership, View Details

Keywords: Healthcare

Richard M. Furlaud

Furlaud focused on Squibb's pharmaceuticals, investing in research and development that ultimately led to the introduction of several new drugs. Furlaud's streamlining and consistent support of the company's cardiovascular drugs paid off... View Details

Keywords: Healthcare

June 2014
Supplement

Merrimack Pharmaceuticals, Inc. (B)

By: Amy C. Edmondson, Bethany Gerstein and Melissa Valentine

In 2006, the leadership team at Merrimack Pharmaceuticals, Inc. had to decide whether to keep its R&D organization in functional departments or restructure it into interdisciplinary teams. This case follows the outcomes of this decision from 2006 to mid-2014, and... View Details

Keywords: Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry

Citation

Purchase

01 Jan 2003
News

Daniel L. Vasella, M.D.

aspirations, purpose, and values, so that they work together as an aligned team." Dan Vasella finds that the skills he called upon as a practicing physician are equally useful in running one of the world's largest pharmaceutical... View Details

April 2023
Case

Elliott Management: Capital Allocation in Biopharma

By: Amitabh Chandra, Paul Clancy and Lauren Gunasti

The case explores the intersection of capital allocation and shareholder activism in the biopharmaceutical industry. As many biopharma companies face looming patent expirations for key medicines, the case asks the question of whether investing in R&D and M&A is an... View Details

Keywords: Finance; Strategy; Capital Allocation; Biopharmaceutical Industry; Shareholder Activism; Investment Activism; Resource Allocation; Research and Development; Business and Shareholder Relations; Corporate Strategy; Pharmaceutical Industry

Citation

Educators

Purchase

September 1993
Supplement

Manufacturing at ALZA: The Right Prescription? (C)

By: Dorothy A. Leonard

ALZA, a drug delivery company, considers marketing its own and other companies' products. The primary issue is whether to build an internal sales force focused on a few niche markets, to finance a sales force through alliances, or to acquire a marketing company. View Details

Keywords: Mergers and Acquisitions; Product Marketing; Alliances; Research and Development; Salesforce Management; Business Strategy; Pharmaceutical Industry

Citation

Find at Harvard

May 2005
Supplement

GlaxoSmithKline: Reorganizing Drug Discovery (B)

By: Robert S. Huckman and Eli Strick

Supplements the (A) case. View Details

Keywords: Mergers and Acquisitions; Decisions; Operations; Performance; Research and Development; Restructuring; Organizations; Pharmaceutical Industry

Citation

Purchase

26 Jul 2016
Working Paper Summaries

The Impact of the Entry of Biosimilars: Evidence from Europe

Keywords: by Fiona Scott Morton, Ariel Dora Stern, and Scott Stern; Pharmaceutical; Pharmaceutical; Pharmaceutical

11 Sep 2019
Research & Ideas

Germany May Have the Answer for Reducing Drug Prices

the Poronui Associate Professor of Business Administration. Pharmaceutical companies have long opposed efforts to regulate drug prices, arguing that prices reflect the companies’ massive research... View Details

Keywords: by Danielle Kost; Health

31 Oct 2004
Research & Ideas

Bypass Marketing: Are Docs Influenced?

Until the close of the last decade, health consumers received much of their knowledge and advice about prescription drugs from their physicians or other health care professionals. Today, pharmaceutical companies are spending several... View Details

Keywords: by Manda Salls

January 2023
Case

Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery

By: Regina Herzlinger and Brian Walker

What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details

Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry

Citation

Educators

Purchase

December 2008 (Revised October 2013)
Case

Amylin Pharmaceuticals: Diabetes and Beyond (A)

By: Richard G. Hamermesh and Rachel Gordon

Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a... View Details

Keywords: Regulations; Drug Regulations; Symlin; Negotiation; Governing Rules, Regulations, and Reforms; Resource Allocation; Negotiation Deal; Product Development; Research and Development; Commercialization; Pharmaceutical Industry; United States

Citation

Educators

Purchase

01 Mar 2016
News

Off Script

according to one study—and the limited lifespan of patent rights. What can the pharmaceutical industry and government regulators do to improve conditions? We put your queries to Fred Hassan (MBA 1972), a managing director at Warburg... View Details

Keywords: Insurance Carriers and Related Activities; Finance

April 2003 (Revised October 2004)
Case

Novartis: The Challenge of Success (B)

By: Sandra J. Sucher and Stacy McManus

When Dr. Daniel Vasella learned of the early Phase 1 trial results, he immediately decided what course of action Novartis would take. Students will be able to examine and assess the concrete steps, and the rationale behind them, that Novartis took in response to this... View Details